TMS Co

TMS Co Treasury Stock

The Treasury Stock of TMS Co (4891.T) as of Nov 4, 2026 is 2.31 B JPY. In the previous year, Treasury Stock was 926.64 M JPY — a change of 149.61% (higher).

Treasury Stock

2.31 BJPY

YoY

149.61%

Last updated:

Treasury Stock of TMS Co is 2026 2.31 B JPY. Treasury Stock of TMS Co was 2025 926.64 M JPY. It decreases by 149.61% higher compared to the previous year.

The TMS Co Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2021
1.63 B JPY
Jan 1, 2022
1.28 B JPY
Jan 1, 2023
2.34 B JPY
Jan 1, 2024
2.68 B JPY
Jan 1, 2025
926.64 M JPY
Jan 1, 2026
2.31 B JPY
The TMS Co Treasury Stock history
YEARTreasury StockYoY
2.31 BJPY+149.61%
926.64 MJPY-65.46%
2.68 BJPY+14.78%
2.34 BJPY+83.14%
1.28 BJPY-21.52%
1.63 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Treasury Stock of TMS Co is 2.31 B JPY in 2026.

Treasury Stock of TMS Co changed from 926.64 M JPY to 2.31 B JPY, representing a 149.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock TMS Co since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — TMS Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — TMS Co